Compound to Aid in Smoking Cessation

Background: Clinical studies have illustrated that tobacco is highly addictive. Paradoxically, nicotine, the psychoactive component in tobacco, is weakly reinforcing in animals. This phenomenon has led researchers to hypothesize that nicotine may interact with other constituents in tobacco smoke to produce its addictive effects. One such constituent is known to be an irreversible, nonselective, monoamine oxidase (MAO) inhibitor, a compound yet to be structurally characterized. Technology: Researchers at the University of California, Irvine (UCI) have shown that monoamine oxidase (MAO) inhibition greatly enhances nicotine self-administration in animals. Through the use of this animal model, which more fully reflects the pharmacological profile of tobacco smoke, researchers at UCI are able to accelerate the development of more effective therapeutic interventions to reduce the incidence of smoking. Application: This compound has already been FDA approved for a non-CNS indication and may be used for smoking cessation.

Type of Offer: Licensing



« More Pharmaceutical Patents

---